Gene: F10
Official Full Name: coagulation factor Xprovided by HGNC
Gene Summary: This gene encodes the vitamin K-dependent coagulation factor X of the blood coagulation cascade. This factor undergoes multiple processing steps before its preproprotein is converted to a mature two-chain form by the excision of the tripeptide RKR. Two chains of the factor are held together by 1 or more disulfide bonds; the light chain contains 2 EGF-like domains, while the heavy chain contains the catalytic domain which is structurally homologous to those of the other hemostatic serine proteases. The mature factor is activated by the cleavage of the activation peptide by factor IXa (in the intrisic pathway), or by factor VIIa (in the extrinsic pathway). The activated factor then converts prothrombin to thrombin in the presence of factor Va, Ca+2, and phospholipid during blood clotting. Mutations of this gene result in factor X deficiency, a hemorrhagic condition of variable severity. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing to generate mature polypeptides. [provided by RefSeq, Aug 2015]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO06813 | F10 Knockout cell line (HCT 116) | Human | F10 | 1:2~1:4 | Negative | Online Inquiry |
F10 Gene Knockout Cell Lines are genetically engineered cell lines designed to study the functional roles of specific genes by completely disrupting their expression. This product is particularly valuable for researchers and clinicians interested in understanding gene function, pathway analyses, and the mechanisms behind various diseases. The F10 platform utilizes advanced CRISPR-Cas9 technology to create precise gene knockouts, ensuring the target gene is rendered inactive while maintaining the integrity of the host genome.
The primary function of these cell lines is to provide a reliable model system to investigate the biological pathways directed by the knocked-out gene. By studying these alterations, researchers can unveil critical insights into cell signaling, metabolic processes, and disease states, effectively contributing to drug discovery, target validation, and functional genomics. In clinical settings, these knockout models help identify potential therapeutic targets and advance personalized medicine approaches.
What sets F10 Gene Knockout Cell Lines apart from other alternatives is their specific design for enhanced reproducibility and stability. Each line comes with comprehensive characterization data, ensuring that users can confidently analyze results without variability often seen in traditional cell lines. Furthermore, compared to conventional knockout strategies, the CRISPR-Cas9 method employed provides a faster and more efficient approach to gene disruption, enabling researchers to accelerate their study timelines.
F10 Gene Knockout Cell Lines are an essential tool for researchers committed to pushing the boundaries of scientific discovery and transforming understanding into therapeutic solutions. With a strong commitment to quality and innovation, our company leverages extensive expertise in genetic engineering and cell biology to deliver outstanding products that empower the scientific community and drive the future of biology-based research.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.